DMAC

NASDAQ

DiaMedica Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2018

$6.32+0.07 (+1.04%)

News25/Ratings6

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Price$6.32+0.25 (+4.04%)

01:30 PM07:45 PM

News · 26 weeks27+300%

2025-10-262026-04-19

Mix790d

SEC Filings3(43%)
Other2(29%)
Earnings2(29%)

Latest news

25 items

23dSEC
SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.
DEFA14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)
23dSEC
SEC Form DEF 14A filed by DiaMedica Therapeutics Inc.
DEF 14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)
25dSEC
SEC Form 10-K filed by DiaMedica Therapeutics Inc.
10-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
25dPR
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal
32dPR
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 31, 2026 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/bxPLk6nkE0q Dial In: (646) 357-8766 Confe
59dPR
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, March 2, 2026, at 11:50 a.m. Eastern Time (ET) Barclays 28th Annual Global Healthcare Conference Miami, Florida Fireside chat with Rick Pauls, CEO on Wednesday, March 10, 2026, at 10:00 a.m. ET Leerink Partners Global Health
66dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by DiaMedica Therapeutics Inc.
SCHEDULE 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
98dPR
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica's common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation. The stock options were approved by the Compensation Committee of the Board of Directors and i
108dINSIDER
Director Parsons James T. was granted 10,095 shares, increasing direct ownership by 11% to 97,949 units (SEC Form 4)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
108dINSIDER
Director Giuffre Randall Michael was granted 6,175 shares, increasing direct ownership by 2% to 398,587 units (SEC Form 4)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
108dINSIDER
Director Semba Charles Pauling was granted 3,355 shares, increasing direct ownership by 8% to 47,963 units (SEC Form 4)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
109dSEC
DiaMedica Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
127dSEC
DiaMedica Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
127dPR
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA's request for one additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre- and postnatal development (PPND) study in a rabbit model. Preparations for this study have commenced, and results are expected to be available by the second quarter of 2026. "
137dINSIDER
Large owner Stahlberg Jan bought $7,631,469 worth of shares (1,061,277 units at $7.19) (SEC Form 4)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
150dINSIDER
Director Parsons James T. exercised 12,000 shares at a strike of $2.20, increasing direct ownership by 16% to 87,854 units (SEC Form 4)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
161dANALYST
Cantor Fitzgerald resumed coverage on DiaMedica Therapeutics
Cantor Fitzgerald resumed coverage of DiaMedica Therapeutics with a rating of Overweight
162dSEC
SEC Form S-8 filed by DiaMedica Therapeutics Inc.
S-8 - DiaMedica Therapeutics Inc. (0001401040) (Filer)
163dSEC
SEC Form 10-Q filed by DiaMedica Therapeutics Inc.
10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
163dSEC
DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
163dPR
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027 Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutica
165dPR
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. Mr. Pauls will deliver a corporate presentation and participate in one-on-one investor meetings during the conference. Details Jefferies Global Healthcare Conference in London Time below is listed in Greenwich Mean Time (GMT) Corporate Presentation: Date: Thursday, November 20, 2025 Time: 10:00-10:25 AM About DiaMedica Therapeutics Inc.
168dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by DiaMedica Therapeutics Inc.
SCHEDULE 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
169dPR
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 13, 2025 Time: 8:00 AM ET /7:00 AM CT Web access: https://app.webinar.net/MlAxZJky3Q7 Dial In: (888) 880-3330 Conference ID: 9449322
172dINSIDER
SEC Form 4 filed by Chief Marketing Officer Krop Julie
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)